| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/26/2001 | CN1071574C Use of 1 alpha, 24-dihydroxy vitamin D2 |
| 09/25/2001 | US6294661 Compounds |
| 09/25/2001 | US6294652 Response regulator |
| 09/25/2001 | US6294583 For threrapy of tic disorders, tourette's syndrome, and blepharospasm, and other focal dystonias |
| 09/25/2001 | US6294561 Cyclic AMP-specific phosphodiesterase inhibitors |
| 09/25/2001 | US6294550 Treatment of female sexual dysfunction |
| 09/25/2001 | US6294546 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 09/25/2001 | US6294538 Antidiabetic agents and diabetic neuropathy, treatment with oxidoreductase enzymes |
| 09/25/2001 | US6294520 Material for passage through the blood-brain barrier |
| 09/25/2001 | US6294517 Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| 09/25/2001 | US6294383 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 09/25/2001 | US6294350 Methods for treating fibroproliferative diseases |
| 09/25/2001 | US6294169 Interleukin-1 beta converting enzyme like apoptotic protease-6 |
| 09/25/2001 | US6294153 Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| 09/24/2001 | WO2003006652A2 Inhibition of specific histone deacetylase isoforms |
| 09/24/2001 | CA2408385A1 Inhibition of specific histone deacetylase isoforms |
| 09/22/2001 | CA2341344A1 Use of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001069252A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | WO2001069240A1 Assay for agents that induce chemokinesis |
| 09/20/2001 | WO2001068861A2 THREE-DIMENSIONAL MODEL OF A Fc REGION OF AN IgE ANTIBODY AND USES THEREOF |
| 09/20/2001 | WO2001068855A2 Gtp-binding protein gamma-12 subunit |
| 09/20/2001 | WO2001068852A2 Apolipoprotein-a-i regulation of t-cell signalling |
| 09/20/2001 | WO2001068848A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | WO2001068720A1 Embolic compositions |
| 09/20/2001 | WO2001068705A2 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | WO2001068704A2 G-protein coupled receptors |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068696A1 Human immune response proteins |
| 09/20/2001 | WO2001068679A2 Peptides targeting specifically tumor-derived endothelial cells |
| 09/20/2001 | WO2001068675A2 Treatment of rosacea |
| 09/20/2001 | WO2001068670A2 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | WO2001068603A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 09/20/2001 | WO2001068146A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/20/2001 | WO2001068137A2 Compositions for regulating memory consolidation |
| 09/20/2001 | WO2001068136A1 Drugs for complications of diabetes and neuropathy and utilization thereof |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068123A2 Monocyte chemoattractant activity of galectin-3 |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068120A2 Uses of bombesin receptor 3 |
| 09/20/2001 | WO2001068104A1 Compounds for the treatment of psychiatric or substance abuse disorders |
| 09/20/2001 | WO2001068098A2 Cephalotaxine alkaloid combination compositions and uses thereof |
| 09/20/2001 | WO2001068093A1 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 09/20/2001 | WO2001068090A1 Microbial inhibitory compositions |
| 09/20/2001 | WO2001068085A1 A method for stimulation of defensin production |
| 09/20/2001 | WO2001068083A1 Use of comt inhibitors as analgesics |
| 09/20/2001 | WO2001068082A1 Treatment and/or prevention of ocular pain |
| 09/20/2001 | WO2001068081A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd) |
| 09/20/2001 | WO2001068073A2 Method for improving respiratory function and inhibiting muscular degeneration |
| 09/20/2001 | WO2001068065A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/20/2001 | WO2001068063A2 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068053A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/20/2001 | WO2001067895A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 09/20/2001 | WO2001067890A2 Composition and method to treat weight gain and obesity attributable to psychotropic drugs |
| 09/20/2001 | WO2001032180A3 Composition for treatment of constipation and irritable bowel syndrome |
| 09/20/2001 | WO2001032029A3 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 09/20/2001 | WO2001030379A3 Compositions and methods for preventing and treating transplant rejection |
| 09/20/2001 | WO2001028579A3 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 09/20/2001 | WO2001028533A3 PRODUCTS AND METHODS FOR ACTIVATING PPARη-RXR AND UP-REGULATING MONOCYTE/MACROPHAGE CD36 FOR THE TREATMENT OF MALARIA |
| 09/20/2001 | WO2001020018A8 Diagnosing and treating arthritic disorders |
| 09/20/2001 | WO2001019819A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 09/20/2001 | WO2001018051A3 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
| 09/20/2001 | WO2001017513A3 Pharmaceutical composition comprising an insulin sensitizer |
| 09/20/2001 | WO2001017479A3 Methods and compositions for preventing and treating prostate disorders |
| 09/20/2001 | WO2001016603A3 Analysis and treatment of body weight and eating disorders |
| 09/20/2001 | WO2001016358A3 Method of screening for triacyglycerol hydrolase inhibitors |
| 09/20/2001 | WO2001015664A3 Coformulation methods and their products |
| 09/20/2001 | WO2001014581A3 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 09/20/2001 | WO2001013953A3 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist |
| 09/20/2001 | WO2001013887A3 Phospholipin gel |
| 09/20/2001 | WO2001010456A3 Peptides that block viral infectivity and methods of use thereof |
| 09/20/2001 | WO2001010427A3 Use of anti-muscarinic agents for treating skin disorders |
| 09/20/2001 | WO2000046246A8 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease |
| 09/20/2001 | WO2000044774A9 Inhibition of stat3 signal transduction for human cancer therapy |
| 09/20/2001 | WO2000043028A9 Method of treating chronic cardiac disease |
| 09/20/2001 | WO2000037066A3 A method for the prophylactic treatment of cataracts |
| 09/20/2001 | WO2000024419A9 Methods for enhancing wound healing |
| 09/20/2001 | WO2000018899A3 Angiotensin converting enzyme homolog and its use |
| 09/20/2001 | WO2000012587A8 Polyamide chains of precise length, methods to manufacture them and their conjugates |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023260 Method for preventing and treating peripheral neuropathy by administering selegiline |
| 09/20/2001 | US20010023258 Mixture with carbonic anhydrase inhibitor |
| 09/20/2001 | US20010023256 Reducing concentration of oxygen metabolites |
| 09/20/2001 | US20010023240 Compounds and compositions for delivering active agents |
| 09/20/2001 | US20010022979 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/20/2001 | US20010022978 Therapy for sensitive skin |
| 09/20/2001 | US20010022975 Topical gel; containing vasodilator |
| 09/20/2001 | US20010022971 IBD-associated microbial nucleic acid molecules |
| 09/20/2001 | US20010022969 Sepsis therapy |
| 09/20/2001 | US20010022965 Colloidal dispersion |
| 09/20/2001 | US20010022964 Fast dissolving orally consumable films |
| 09/20/2001 | DE10013578A1 Use of 3,4-dihydroxymandelic acid and/or stereoisomers as antioxidants and/or radical scavengers in protecting mammalian skin, cosmetic or pharmaceutical preparations, foodstuffs, lacquers and polymers |
| 09/20/2001 | DE10011541A1 Water additive for increasing vitality of bony fish, comprising combination of ephedrine and caffeine and/or theophylline, especially useful for combating transport stress |
| 09/20/2001 | CA2403442A1 Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403220A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | CA2403201A1 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | CA2403084A1 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia" |
| 09/20/2001 | CA2402940A1 G-protein coupled receptors |